Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Meta Expands AI Training With Employee Activity Tracking Tools 
LOS ANGELES, March 31, 2017 -- Lundin Law PC , a shareholder rights firm, announces a class action lawsuit against Regulus Therapeutics Inc. (“Regulus” or the “Company”) (Nasdaq:RGLS) concerning possible violations of federal securities laws between January 21, 2016 and June 27, 2016 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the April 3, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Regulus made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects. On June 27, 2016, the Company announced that it received notice from the U.S. Food and Drug Administration (“FDA”) that its new drug for the treatment of chronic hepatitis C virus infection which was under FDA review, is now being put on clinical hold after a second serious case of jaundice was reported. When this information was released, the stock price of Regulus fell, causing investors harm.
Lundin Law PC was established by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
